{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T08:42:32Z","timestamp":1795164152193,"version":"4.10.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","award":["NIHR"],"award-info":[{"award-number":["NIHR"]}],"id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030827","name":"NHS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002141","name":"Public Health England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Considerable data support early treatment of RA to obtain disease remission. Data from the National Early Inflammatory Arthritis Audit (NEIAA) in England and Wales suggest that, despite recent improvements in referral-to-treatment times, remission rates remain unchanged. We investigated reasons for this disconnect by evaluating temporal trends, geographical variation and predictors of remission in individuals with new RA diagnoses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An observational cohort study of individuals with RA was conducted using data from NEIAA (May 2018\u2013April 2024). Temporal and geographical variation in remission rates (DAS28\u2009&amp;lt;\u20092.6) were explored using interrupted time-series and case-mix-adjusted mixed-effects regression. Predictors of remission were assessed using multivariable logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>13\u2009752 of 21\u2009904 (62.8%) individuals with RA had data on DAS28 at 3\u2009months after initial rheumatology assessment, of whom 4764 (34.6%) achieved remission. National remission rates were stable from 2018 to 2024; however, wide geographical variation was observed, ranging from 28.4% (London) to 40.3% (East of England). Threefold differences in remission rates were seen between individual hospitals within regions. Younger age, female sex, Black ethnicity, higher baseline DAS28, delayed DMARD initiation and longer symptom duration were independently associated with reduced odds of remission. Delays between symptom onset and referral have increased since the COVID-19 pandemic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>While national remission rates for early RA have remained stable in England and Wales since 2018, there is marked regional and hospital-level variation, highlighting ongoing inequities in service delivery. Addressing factors beyond referral-to-treatment time\u2014particularly delayed presentation to primary care\u2014is required to improve remission rates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf233","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:12:33Z","timestamp":1746177153000},"page":"4957-4967","source":"Crossref","is-referenced-by-count":6,"title":["Trends in remission rates for rheumatoid arthritis in England and Wales: a population-level cohort study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-6194","authenticated-orcid":false,"given":"Edward","family":"Alveyn","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]},{"name":"Department of Rheumatology, King's College Hospital NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Coalwood","sequence":"additional","affiliation":[{"name":"British Society for Rheumatology , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e1inne","family":"Farrell","sequence":"additional","affiliation":[{"name":"British Society for Rheumatology , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Jackson","sequence":"additional","affiliation":[{"name":"British Society for Rheumatology , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-6603","authenticated-orcid":false,"given":"Maryam A","family":"Adas","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]},{"name":"Department of Rheumatology, King's College Hospital NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-9963","authenticated-orcid":false,"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]},{"name":"Institute of Psychiatry, Psychology & Neuroscience, King's College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lanyon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nottingham University Hospitals NHS Trust , Nottingham,","place":["UK"]},{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-0201","authenticated-orcid":false,"given":"Elizabeth","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Great Western Hospital NHS Foundation Trust , Swindon,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M","family":"Ledingham","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Portsmouth Hospitals University NHS Trust , Portsmouth,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James B","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]},{"name":"Department of Rheumatology, King's College Hospital NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7772","authenticated-orcid":false,"given":"Mark D","family":"Russell","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]},{"name":"Department of Rheumatology, King's College Hospital NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"2025090315122329300_keaf233-B1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","article-title":"Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts","volume":"74","author":"van Nies","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090315122329300_keaf233-B2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12325-021-01946-w","article-title":"Value of remission in patients with rheumatoid arthritis: a targeted review","volume":"39","author":"Ostor","year":"2022","journal-title":"Adv Ther"},{"key":"2025090315122329300_keaf233-B3","author":"NICE","year":"2018"},{"key":"2025090315122329300_keaf233-B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025090315122329300_keaf233-B5","author":"NICE","year":"2020"},{"key":"2025090315122329300_keaf233-B6","author":"British Society for Rheumatology","year":"2025"},{"key":"2025090315122329300_keaf233-B7","author":"British Society for Rheumatology","year":"2024"},{"key":"2025090315122329300_keaf233-B8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American College of Rheumatology\/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025090315122329300_keaf233-B9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The disease activity score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090315122329300_keaf233-B10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1536867X1501500208","article-title":"Conducting interrupted time-series analysis for single- and multiple-group comparisons","volume":"15","author":"Linden","year":"2015","journal-title":"Stata J"},{"key":"2025090315122329300_keaf233-B11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \"second-line\" antirheumatic drugs. A randomized, controlled trial","volume":"124","author":"van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"key":"2025090315122329300_keaf233-B12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315122329300_keaf233-B13","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1002\/art.27692","article-title":"Long-term impact of delay in assessment of patients with early arthritis","volume":"62","author":"van der Linden","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025090315122329300_keaf233-B14","author":"Royal College of General Practitioners","year":"2024"},{"key":"2025090315122329300_keaf233-B15","author":"British Medical Association","year":"2024"},{"key":"2025090315122329300_keaf233-B16","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/S2589-7500(21)00279-X","article-title":"Remote general practitioner consultations during COVID-19","volume":"4","author":"Green","year":"2022","journal-title":"Lancet Digital Health"},{"key":"2025090315122329300_keaf233-B17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090315122329300_keaf233-B18","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator\u2013controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090315122329300_keaf233-B19","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"2025090315122329300_keaf233-B20","doi-asserted-by":"crossref","first-page":"e003027","DOI":"10.1136\/rmdopen-2023-003027","article-title":"Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts","volume":"9","author":"Westerlind","year":"2023","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf233\/63054940\/keaf233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4957\/63054940\/keaf233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4957\/63054940\/keaf233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:12:29Z","timestamp":1756926749000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/4957\/8125034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,5]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf233","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,5]]}}}